Dr. Kahl Discusses Unmet Needs in MCL

Video

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses unmet needs in the treatment landscape of mantle cell lymphoma.

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses unmet needs in the treatment landscape of mantle cell lymphoma (MCL).

Kahl says that the biggest unmet need in MCL is the lack of curative options, particularly with the rate of relapse being so high. This begins with improving outcomes in the frontline setting, and there are multiple novel targeted agents that are showing good activity in MCL, such as ibrutinib (Imbruvica), acalabrutinib (Calquence), and venetoclax (Venclexta). There is also interest in combination therapy with these novel agents and current standard therapies.

Ibrutinib is currently approved for relapsed disease, and is used frequently to treat these patients. It is being tested now in the frontline setting in the SHINE trial. The SHINE trial is a phase III trial of ibrutinib in combination with bendamustine and rituximab (Rituxan) in older patients with newly diagnosed MCL. The study aims to evaluate the safety and efficacy of the combination.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,